Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
Inmune Bio, Inc. INMB

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Sep 14, 2026 8-K 10 signals fired
Other
Executive Educational Background Disclosure Rsu Psu Vesting Schedule Disclosed Employee Director Compensation Waiver Classified Board Director Election Board Committee Member Listing Audit Committee Independence Certification Gene Therapy Aav
Core
Lead Asset Progress Indication Expansion
Biotech v3
Ai Drug Discovery Investment
Aug 6, 2026 10-Q 16 signals fired · top 15
Other
Net Loss Reported Ipo Or Capital Raising Completion Administrative Efficiency Revenue Increase Attribution Disclosure Goodwill Impairment Institutional Investment Personnel Cost Decrease Disclosure Inlicensing Deal Completed Other Income Expense Disclosure Interest Income Year Over Year Comparison Impairment Charge Breakdown Liquidity Position Snapshot Disclosed
Biotech Risk
Trial Endpoint Missed
Core
Indication Expansion Enrollment Failure
Jul 1, 2026 8-K 5 signals fired
Other
Corporate Organization And Standing Representation Corporate Authority Representation Exchange Offer Letter Of Transmittal Survival Of Representations Warranties Clause Exchange Offer Expiration Disclosed
Jun 23, 2026 8-K 11 signals fired
Core
Indication Expansion Lead Asset Progress Clinical Trial Result
Other
Interim Data Positive Fda Aligned Gene Therapy Aav Fast Track Designation Received Kol Endorsement Publication Positive
Biotech Risk
Trial Endpoint Missed
Biotech v3
Ai Drug Discovery Investment
Jun 17, 2026 8-K 2 signals fired
Other
Auditor Appointment Ratification Classified Board Director Election
Jun 2, 2026 8-K 19 signals fired · top 15
Core
Clinical Trial Result Indication Expansion Lead Asset Progress Secondary Endpoint Mentioned
Other
Interim Data Positive Fda Aligned Enrollment Ahead Of Schedule Protocol Amended Ceo Team Pride Statement Fast Track Designation Received Gene Therapy Aav Expanded Access Program Active Fast Track Granted Patient Retention High
Biotech v3
Ai Drug Discovery Investment
May 14, 2026 8-K 12 signals fired
Core
Regulatory Designation Only Clinical Trial Result Indication Expansion Lead Asset Progress
Other
Fast Track Designation Received Fast Track Granted Orphan Status Granted Enrollment Ahead Of Schedule Breakthrough Therapy Granted Fda Aligned Safety Differentiated
Biotech Risk
Orphan Drug Designation
May 7, 2026 10-Q 9 signals fired
Other
Net Loss Reported Liquidity Position Snapshot Disclosed Safety Differentiated Inlicensing Deal Completed Institutional Investment Critical Accounting Policies Disclosure Other Income Expense Disclosure
Core
Indication Expansion
Biotech v3
Ai Drug Discovery Investment
May 5, 2026 8-K 5 signals fired
Other
Confidential Information Return Obligation Kol Endorsement Ceo Team Pride Statement Indemnification Consent Requirement
Core
Indication Expansion
Mar 30, 2026 10-K 67 signals fired · top 15
Other
Competition Disclosure Net Loss Reported Nyse Listing Disclosure Reimbursement Price Pressure Risk Codm Segment Reporting Disclosure Warrant Valued Black Scholes Material Weakness In Internal Controls Disclosed Patent Family Portfolio Disclosure Cybersecurity Breach Reputational Harm Disclosure Anti Takeover Provision Disclosure Ip Protection Methods Disclosed Capital Raising Uncertainty Disclosed Nol Carryforward Expiration Disclosure Hipaa Fraud Abuse Laws Disclosure
Core
Regulatory Designation Only